What is Tissue Heart Valves?
Tissue Heart Valves are also known as the biosynthetic valves, these are harvested from the pig heart valves (porcine) or from the sac surrounding the heart of the cow (bovine). Certain tissue valves are mounted on the frame or stent while others are used directly (stentless).
What is the market for Global Tissue Heart Valves?
Global Tissue Heart Valves Market was valued at USD XX billion in 2020, growing at a CAGR of XX during the forecast period from 2021 to 2026.
For more information, click here @ Tissue Heart Valves Competitive
What are the drivers for Global Tissue Heart Valves?
The major drivers driving the demand for Tissue Heart Valves are the increasing prevalence of heart valve diseases such as aortic valve degeneration and aortic stenosis, the rising demand for minimally invasive procedures, improved technological advancements of the tissue heart valves and longer life expectancy of the geriatric population.
What are the key players operating in Global Tissue Heart Valves?
Some of the key market players operating in the Tissue Heart Valves market includes Abbott, Boston Scientific Corporation, CryoLife, Inc., Edward Lifesciences Corporation, Medtronic, Sorin Group (LivaNova PLC), and others.
What regions has the highest share in Tissue Heart Valves market?
North America is expected to dominate the overall Tissue Heart Valves market during the forecast period, 2021 to 2026. This domination is due to the rising prevalence of heart valvular diseases, rising product approvals in the North American region and increasing reimbursement policies pertaining to the tissue heart valves.
Recent Developmental Activities in Tissue Heart Valves Market:
· On May 13, 2021, FDA had approved the Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve (THV) System to replace a diseased heart valve without open-heart surgery.
· On December 14, 2020, Foldax®, Inc. had announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval for the company to initiate a U.S. clinical study of its Tria™ biopolymer mitral surgical heart valve.
· On September 10, 2020, the leading transcatheter heart valve medical device player in China had announced their joint venture with Jilin Changchun Haoyue Halal Meat Co., Ltd (""Haoyue Group""). The Venus Medtech and Venus Haoyue Medtech are aiming to provide total treatment solutions for heart valve diseases from the source of biomaterials.
Request for sample pages @ Tissue Heart Valves Market Forecast